

Date: 23rd September, 2019

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Tower, Dalal Street,
Fort, Mumbai – 400 001

Dear Sir/Madam,


Sub: Alembic Pharmaceuticals Limited announces completion of USFDA Inspection at Aleor Dermaceuticals Limited

With reference to the captioned subject, this is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; with one observation. The inspection was carried out from 16th September, 2019 to 20th September, 2019.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

Date: 23rd September, 2019

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals Limited announces completion of USFDA
Inspection at Aleor Dermaceuticals Limited**

With reference to the captioned subject, this is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; with one observation. The inspection was carried out from 16th September, 2019 to 20th September, 2019.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED